Division of Infectious Diseases, Weill Cornell Medical Center of Cornell University, New York, NY 10065, USA.
Clin Infect Dis. 2012 Nov 15;55(10):1338-51. doi: 10.1093/cid/cis660. Epub 2012 Aug 21.
The epidemiology, pathogenesis, clinical manifestations, management, and outcome of Candida osteomyelitis are not well understood.
Cases of Candida osteomyelitis from 1970 through 2011 were reviewed. Underlying conditions, microbiology, mechanisms of infection, clinical manifestations, antifungal therapy, and outcome were studied in 207 evaluable cases.
Median age was 30 years (range, ≤ 1 month to 88 years) with a >2:1 male:female ratio. Most patients (90%) were not neutropenic. Localizing pain, tenderness, and/or edema were present in 90% of patients. Mechanisms of bone infection followed a pattern of hematogenous dissemination (67%), direct inoculation (25%), and contiguous infection (9%). Coinciding with hematogenous infection, most patients had ≥2 infected bones. When analyzed by age, the most common distribution of infected sites for adults was vertebra (odds ratio [OR], 0.09; 95% confidence interval [CI], .04-.25), rib, and sternum; for pediatric patients (≤18 years) the pattern was femur (OR, 20.6; 95% CI, 8.4-48.1), humerus, then vertebra/ribs. Non-albicans Candida species caused 35% of cases. Bacteria were recovered concomitantly from 12% of cases, underscoring the need for biopsy and/or culture. Candida septic arthritis occurred concomitantly in 21%. Combined surgery and antifungal therapy were used in 48% of cases. The overall complete response rate of Candida osteomyelitis of 32% reflects the difficulty in treating this infection. Relapsed infection, possibly related to inadequate duration of therapy, occurred among 32% who ultimately achieved complete response.
Candida osteomyelitis is being reported with increasing frequency. Localizing symptoms are usually present. Vertebrae are the most common sites in adults vs femora in children. Timely diagnosis of Candida osteomyelitis with extended courses of 6-12 months of antifungal therapy, and surgical intervention, when indicated, may improve outcome.
白色念珠菌性骨髓炎的流行病学、发病机制、临床表现、治疗和预后尚不清楚。
对 1970 年至 2011 年间的白色念珠菌性骨髓炎病例进行了回顾性分析。对 207 例可评估病例进行了基础疾病、微生物学、感染机制、临床表现、抗真菌治疗和预后研究。
中位年龄为 30 岁(范围为 1 个月至 88 岁),男女比例为 2:1 以上。大多数患者(90%)无中性粒细胞减少症。90%的患者有局部疼痛、压痛和/或肿胀。骨感染的机制为血行播散(67%)、直接接种(25%)和相邻感染(9%)。与血行感染同时发生时,大多数患者有≥2 处感染骨骼。按年龄分析,成人最常见的感染部位分布为椎体(比值比 [OR],0.09;95%置信区间 [CI],0.04-0.25)、肋骨和胸骨;儿科患者(≤18 岁)为股骨(OR,20.6;95%CI,8.4-48.1)、肱骨、然后是椎体/肋骨。非白念珠菌属念珠菌引起 35%的病例。12%的病例同时分离出细菌,强调了活检和/或培养的必要性。21%的病例同时发生念珠菌性化脓性关节炎。48%的病例采用手术联合抗真菌治疗。32%的白色念珠菌性骨髓炎完全缓解率反映了治疗这种感染的难度。最终完全缓解的患者中有 32%出现复发感染,可能与治疗时间不足有关。
白色念珠菌性骨髓炎的报道频率正在增加。通常有局部症状。成人最常见的部位是椎体,而儿童则是股骨。通过延长 6-12 个月的抗真菌治疗,并在需要时进行手术干预,及时诊断白色念珠菌性骨髓炎,可能会改善预后。